ATE549404T1 - Verfahren zum screening eines transmembranenzymhemmstoffs - Google Patents
Verfahren zum screening eines transmembranenzymhemmstoffsInfo
- Publication number
- ATE549404T1 ATE549404T1 AT05790422T AT05790422T ATE549404T1 AT E549404 T1 ATE549404 T1 AT E549404T1 AT 05790422 T AT05790422 T AT 05790422T AT 05790422 T AT05790422 T AT 05790422T AT E549404 T1 ATE549404 T1 AT E549404T1
- Authority
- AT
- Austria
- Prior art keywords
- transmembrane
- enzyme
- protein
- region
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004290784 | 2004-10-01 | ||
PCT/JP2005/018587 WO2006038684A1 (ja) | 2004-10-01 | 2005-09-30 | 膜貫通型酵素阻害物質のスクリーニング方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE549404T1 true ATE549404T1 (de) | 2012-03-15 |
Family
ID=36142754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05790422T ATE549404T1 (de) | 2004-10-01 | 2005-09-30 | Verfahren zum screening eines transmembranenzymhemmstoffs |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080220445A1 (de) |
EP (1) | EP1801232B1 (de) |
JP (1) | JP4778906B2 (de) |
AT (1) | ATE549404T1 (de) |
WO (1) | WO2006038684A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2638070B1 (de) | 2010-11-10 | 2016-10-19 | F.Hoffmann-La Roche Ag | Verfahren und zusammensetzungen zur immuntherapie bei nervenerkrankungen |
WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
US10882920B2 (en) | 2014-11-19 | 2021-01-05 | Genentech, Inc. | Antibodies against BACE1 and use thereof for neural disease immunotherapy |
CN107523579A (zh) * | 2017-09-08 | 2017-12-29 | 东北师范大学 | 促进大脑中Aβ累积的BACE1亚型的功能研发及应用 |
CN107475260B (zh) * | 2017-09-08 | 2020-12-04 | 东北师范大学 | 抑制大脑中Aβ累积的BACE1亚型的功能研发及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0667959T3 (da) | 1992-10-26 | 2003-12-08 | Elan Pharm Inc | Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid |
CZ184194A3 (en) | 1993-08-09 | 1995-03-15 | Lilly Co Eli | Aspartylprotease inhibitor and method of identifying thereof |
CA2321962C (en) * | 1998-02-27 | 2014-07-15 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | G protein-coupled receptor antagonists |
US6699671B1 (en) * | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
WO2000024780A2 (en) | 1998-10-26 | 2000-05-04 | Genzyme Corporation | Compositions and methods for treating polycystic kidney disease |
US20040110743A1 (en) * | 2000-05-19 | 2004-06-10 | Masaomi Miyamato | -Secretase inhibitors |
JP2002037731A (ja) * | 2000-05-19 | 2002-02-06 | Takeda Chem Ind Ltd | βセクレターゼ阻害剤 |
US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
US6562783B2 (en) * | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
CH698246B1 (de) | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
EP1459764A4 (de) * | 2001-12-26 | 2006-08-16 | Takeda Pharmaceutical | Mittel zur behandlung von leichten erkennungsstörungen |
-
2005
- 2005-09-30 JP JP2006539339A patent/JP4778906B2/ja not_active Expired - Fee Related
- 2005-09-30 AT AT05790422T patent/ATE549404T1/de active
- 2005-09-30 US US11/664,086 patent/US20080220445A1/en not_active Abandoned
- 2005-09-30 WO PCT/JP2005/018587 patent/WO2006038684A1/ja active Application Filing
- 2005-09-30 EP EP05790422A patent/EP1801232B1/de not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
EP1801232A4 (de) | 2008-12-10 |
JP4778906B2 (ja) | 2011-09-21 |
EP1801232B1 (de) | 2012-03-14 |
US20080220445A1 (en) | 2008-09-11 |
WO2006038684A1 (ja) | 2006-04-13 |
JPWO2006038684A1 (ja) | 2008-05-15 |
EP1801232A1 (de) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE496021T1 (de) | Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen | |
EA200100992A1 (ru) | Ингибиторы фермента impdh | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
WO2005082343A3 (en) | Amines and amides for the treatment of diseases | |
ATE556711T1 (de) | Verfahren zur verbesserung der hautqualität | |
CY1108689T1 (el) | Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα | |
PT966465E (pt) | Inibidores do enzima imfdh | |
CY1111212T1 (el) | Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ | |
EA200700117A1 (ru) | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов | |
NO20074697L (no) | Ikke-aromatisk, nitrogenholdig heterosyklisk-1-karboksylatester-pyridylderivat | |
BRPI0511111A (pt) | compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
ATE506456T1 (de) | Verfahren zur behandlung von lentivirusinfektionen | |
EA200701257A1 (ru) | Пирролопиразолы в качестве сильнодействующих ингибиторов киназы | |
DE602004024572D1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
WO2006034296A3 (en) | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof | |
ATE549404T1 (de) | Verfahren zum screening eines transmembranenzymhemmstoffs | |
ATE435858T1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen | |
CY1110185T1 (el) | Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19 | |
ATE550661T1 (de) | Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörper | |
DE602004012578D1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
NO20061575L (no) | Fremgangsmate for fremstilling av renzapride og mellomprodukter derav | |
MA29554B1 (fr) | Nouveaux derives d'amide d'acide piperidine carboxylique | |
DK1539724T3 (da) | Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet | |
WO2003099202A3 (en) | Beta-secretase inhibitors |